ASX:FRE

Firebrick Pharma (FRE) Stock Price, News & Analysis

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Firebrick Pharma alerts:

Ad Stansberry Research

BUY ALERT: Tiny tech play partners with US government

The Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).

Get the full story here while you can.

About Firebrick Pharma

Firebrick Pharma Limited engages in the development and partnering of broad-spectrum antimicrobial spray for the treatment of common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.

Ad Stansberry Research

BUY ALERT: Tiny tech play partners with US government

Get the full story here while you can.

FRE Stock News Headlines

July 4 at 7:00 AM | americanbankingnews.com

Firebrick Pharma Limited (ASX:FRE) Insider Buys A$28,500.00 in Stock

See More Headlines

Receive FRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Firebrick Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Drug Manufacturers - General
Sub-Industry: N/A
Current Symbol: ASX:FRE
CUSIP: N/A
CIK: N/A
Web: www.firebrickpharma.com
Phone: 1300 301 874
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,570,000.00
Net Margins: -251.57%
Pretax Margin: N/A
Return on Equity: -136.04%
Return on Assets: -74.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.17
Quick Ratio: 18.29

Sales & Book Value

Annual Sales: $1.82 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: A$0.01 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 179,310,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.67

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. Peter Laurence Molloy BSc (Age 70)
FAICD, MBA, Founder, Executive Chairman & CEO
Comp: $351.3k
Dr. Stephen Francis Goodall MASc
MBA, Founder, COO & Executive Director
Mr. Kavi Bekarma B.Sc.
C.A., Chief Financial Officer
Dr. Simon Tucker
Chief Scientific Officer
Prof. Peter Friedland
Chief Medical Officer
Dr. Monique Baldwin
Head of Regulatory Affairs
Mr. Stephen Buckley
Company Secretary